MedPath

Targeted Abdominal CT in Conjunction With Lung Cancer Screening

Not Applicable
Not yet recruiting
Conditions
Renal Cell Carcinoma (Kidney Cancer)
Kidney Cancers
AAA - Abdominal Aortic Aneurysm
Renal Stones
Registration Number
NCT07171190
Lead Sponsor
University of Cambridge
Brief Summary

Early detection through screening can improve cancer survival by identifying it when it's most treatable. The NHS now offers Lung Cancer Screening (LCS) assessments to people aged 55-74 who have ever smoked. Those at higher risk of lung cancer are offered a lung scan.

This group also has a high risk of developing abdominal cancers, such as kidney cancer. A recent study explored whether it would be feasible to extend the lung scan to include the abdomen. Results showed most participants supported this addition, and the number of serious findings was similar to those detected in UK breast or bowel cancer screening programmes.

However, the abdominal scan was only offered on the day of the lung scan, giving little time for people to consider their decision. The process also added too much time to be practical for widespread implementation.

This new study will:

* Test whether mentioning the possible abdominal scan in the initial LCS invitation affects participation in LCS assessments.

* Test new processes to assess if the abdominal scan can be added to the lung scan with minimal extra time.

* Check if participants can be split between the lung scan only group and lung and abdominal scan group using an approach called 'cluster randomisation'. This will be important in case a bigger trial is needed.

* See whether the additional processes are acceptable

People aged 55-70 who are invited to the lung cancer screening will be eligible to take part in this study. Only those who are found to be at a high risk of lung cancer after their assessment, and therefore offered a lung scan, will be offered the abdominal scan, provided they have not had an abdominal scan in the previous 12 months or one booked in the next 3 months.

This study will take place in two existing lung cancer screening locations in Yorkshire.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
6272
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Attendance rate at the LCS phone call12 weeks after invitation letter is sent

Attendance rate of the invitation intervention group to the LCS phone call is non-inferior to the attendance rate of the invitation control group and if so, whether it is superior.

Cluster randomisation assessmentAt the point of LCS assessment, within 12 weeks of invitation

Successful cluster randomisation of participants into scan control and scan intervention groups as demonstrated by groups of similar size.

Impact of abdominal scan on throughputUp to 6 months after invitation

Average number of participants scanned per standard LCS scanning day is no different when adding the ANCCT

Perceived impact of abdominal scan on throughputUp to 6 months after invitation

Data from daily short questionnaire completed by scanning unit staff shows perceived impact of TACTICAL activities on normal LCS processes is no different when ANCCT is added for at least 80% of days

Incremental time taken for each TACTICAL1 task compared with the existing LCS processes.Up to 6 months after invitation

The observed incremental time taken for each TACTICAL1 task compared with the existing LCS processes for a sub-sample of participants.

Over 75% of participants receiving abdominal scan are satisfied or very satisfied with their scanning unit experienceUp to 6 months after invitation

Over 75% of participants are satisfied or very satisfied with their scanning unit experience as demonstrated by a post-scan feedback questionnaire.

Secondary Outcome Measures
NameTimeMethod
Percentage of participants taking up offer of abdominal scanUp to 6 months after invitation.

At least 80% of participants offered the ANCCT, accept the invitation and attend the scan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.